SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Mural Oncology plc

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Mural Oncology plc, holding 1,722,000 ordinary shares as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 3 to their Schedule 13G, disclosing their beneficial ownership in Mural Oncology plc.
• The Reporting Persons collectively beneficially own 1,722,000 ordinary shares of Mural Oncology plc.
• This ownership represents 9.99% of the outstanding ordinary shares of Mural Oncology plc.
• The percentage is calculated based on 17,228,291 shares outstanding as of February 28, 2025, as reported in the Issuer's Form 10-K filed on March 11, 2025.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares are reported to be acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual and routine regulatory disclosure of beneficial ownership. It does not contain explicit positive or negative sentiment regarding the issuer's performance or outlook, nor does it imply any immediate strategic action beyond passive investment.

Positives

• The disclosure of a significant stake (9.99%) by an institutional investor like Armistice Capital, LLC, and its managing member, Steven Boyd, can be viewed as a signal of confidence in Mural Oncology plc by these investors.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.

Management Comments

• The Reporting Persons certify that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a routine regulatory disclosure of a significant passive investment by an institutional investor in a publicly traded company. It reflects a standard practice for investment firms to report their beneficial ownership stakes exceeding 5% in accordance with SEC regulations.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding the ownership structure of Mural Oncology plc, indicating a significant stake held by institutional investors Armistice Capital, LLC and Steven Boyd.

Key Dates

Keywords

Mural Oncology plc, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, ordinary shares, investment management, SEC filing